Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018

Safaev, Khasan; Parpieva, Nargiza; Liverko, Irina; Yuldashev, Sharofiddin; Dumchev, Kostyantyn; Gadoev, Jamshid; Korotych, Oleksandr; Harries, Anthony

doi:10.3390/ijerph18094663

Cited by 16 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TB regimens and dosing of required TB drugs were extracted from TB program guidelines for Karakalpakstan [54] and Uzbekistan [55], WHO guidelines [5], TB trial registrations on Clini-calTrials.gov [11][12][13][17][18][19], and MSF Access Campaign reporting. All-oral TB regimens were extracted from the MSF Access Campaign report 2020, TB regimens including an injectable antibiotic were extracted from MSF Access Campaign reports 2018-20 [42][43][44].…”

Section: Data Sourcesmentioning

confidence: 99%

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Köhler

Sitali²,

Achar

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global Drug Facility, they can incur import costs for international transport, customs clearance, and national transport. We assessed the drug costs and import costs of 18 longer (≥18 months), 10 shorter (9–12 months), and 8 short (≤6 months) drug regimens for drug-sensitive (DS) and multidrug-resistant (MDR)-TB treatment. Costs per regimen were estimated by multiplying recommended drug amounts with 2021 Global Drug Facility prices and drug import costs of a TB program in Karakalpakstan, Uzbekistan. The standard short-course treatment of DS-TB requires taking 730 fixed-dose combination tablets, which weigh 0.79 kg and cause an import cost of $4.19 (9.8% of the regimen’s drug cost of $43). A new 4-month DS-TB regimen requires taking 1358 tablets, which weigh 1.1 kg and cause an import cost of $6.07 (2.6% of the regimen’s drug cost of $233). MDR-TB regimens that last between 24 weeks and 20 months involve 546–9368 tablets and injections. The drugs for these MDR-TB regimens were estimated to weigh 0.42–96 kg and cause an import cost of $2.26–507 per drug regimen (0.29–11% of a regimen’s drug cost of $360–15,028). In a multivariable regression analysis, an additional treatment month increased the import cost of a drug regimen by $5.45 (95% CI: 1.65 to 9.26). Use of an injectable antibiotic in a regimen increased the import cost by $133 (95% CI: 47 to 219). The variable and potentially sizable import costs of TB regimens can affect the financial needs of TB programs. Drug regimens that are shorter and all-oral tend to reduce import costs compared to longer regimens and regimens including an injectable drug.

show abstract

Section: Data Sourcesmentioning

confidence: 99%

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Köhler

Sitali²,

Achar

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

show abstract

“…MDR-TB patients which undergo Linezolid treatment was dominated by male (52.6%). A study by Safaev et al and Jaspard et al supported this result (7,12). This phenomenon could be explained by the increase susceptibility to infection that is caused by men related factors such as smoking that could cause toxic lung injury and reduced immune cell function and alcohol consumption that have immunosuppressive effects.…”

Section: International Journal Of Scientific Advances Issn: 2708-7972mentioning

confidence: 86%

Adverse Effects of Linezolid in Tuberculosis Patients at Dr. Soetomo General Hospital Surabaya

Sutantyo¹,

Agustini²,

Kusmiati³

2023

International Journal of Scientific Advances

View full text Add to dashboard Cite

An infectious respiratory disease known as tuberculosis (TB) is commonly treated with Linezolid when it is considered as drug resistant. However, Linezolid has several severe adverse effects. This study aims to give a better depiction of TB patients treated with Linezolid. This retrospective cohort designed study was conducted at Dr. Soetomo General Hospital Surabaya using secondary data obtained from medical record. The data collected were patient’s identity, tuberculosis type based on its drug resistance, the therapy duration, and the adverse effect experienced by subjects. Male patients dominated the study’s population (52.6%) with most patients were aged 40-60 years old (55.3%). Most of the patients had MDR TB (n = 27) and treated for ≥6 months (n = 33). Myelosuppression became the most common adverse effects in this study (31.6%). TB patients who undergo prolonged Linezolid therapy tend to experience adverse effects.

show abstract

“…For instance, Atadjan et al stated that TB incidence showed a stable decline in the Russian Federation over the past 20 years, while Kozhoyarova et al revealed that there was a slow decline in TB mortality in Kyrgyzstan from 2007 to 2017 26 27. Safaev and coworkers informed that reported TB cases dropped significantly in Uzbekistan over the last 20 years 28…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014–2019

Sakko,

Madikenova,

Kim

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesThis study aims to estimate tuberculosis (TB) incidence, mortality rates and survival HRs in Kazakhstan, using large-scale administrative health data records during 2014–2019.DesignA retrospective cohort study.SettingsData for patients with TB in Kazakhstan during 2014–2019, reported in the Unified National Electronic Healthcare System.ParticipantsPatients with TB in Kazakhstan (ICD-10 (The International Classification of Diseases, 10th revision) codes: A15–A19).Outcome measuresDemographic factors, diagnoses and comorbidities were analysed using descriptive, bivariate and multivariable statistical analyses. TB incidence and mortality rates were calculated, and Cox regression and Kaplan-Meier survival analysis were performed to assess risk factors for survival rates.ResultsOf the 149 122 patients with TB, 91 437 (61%) were males, and 139 931 (94%) had respiratory TB. From 2014 to 2019, TB incidence declined from 227 to 15.2 per 100 000 individuals, while all-cause mortality increased from 8.4 to 15.2 per 100 000. Age-specific TB incidence was lowest for 0–10 years of age and highest for 20 years of age. Being older, man, urban residence versus rural, retired versus employed, having HIV and having diabetes versus no comorbidities were associated with lower survival rates.ConclusionTo date, this is the largest TB published study for Kazakhstan, characterising TB incidence and mortality trends by demographic factors, and risk factors for survival rates. The findings highlight the need for targeted interventions to address the growing burden of TB, particularly among older adults, men, urban residents and those with HIV and diabetes. The study underscores the importance of using administrative health data to inform policy and health system responses to TB in Kazakhstan.

show abstract

Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013–2018

Cited by 16 publications

References 31 publications

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Adverse Effects of Linezolid in Tuberculosis Patients at Dr. Soetomo General Hospital Surabaya

Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014–2019

Contact Info

Product

Resources

About